BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Palmer BF, Clegg DJ. Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. Clin J Am Soc Nephrol 2021;16:1284-91. [PMID: 33563658 DOI: 10.2215/CJN.17621120] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Marcińczyk N, Misztal T, Chabielska E, Gromotowicz-Popławska A. Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice. Sci Rep 2023;13:932. [PMID: 36650229 DOI: 10.1038/s41598-023-28225-8] [Reference Citation Analysis]
2 Zhao Z, Zhao F, Zhang Y, Hu X, Li J, Tian C, Jin P, Liu D. Risk factors of dapagliflozin-associated diabetic ketosis/ketoacidosis in patients with type 2 diabetes mellitus: A matched case-control study. Diabetes Res Clin Pract 2023;196:110236. [PMID: 36610546 DOI: 10.1016/j.diabres.2023.110236] [Reference Citation Analysis]
3 Sitina M, Lukes M, Sra V. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis.. [DOI: 10.21203/rs.3.rs-2308651/v1] [Reference Citation Analysis]
4 Yaribeygi H, Maleki M, Butler AE, Jamialahmadi T, Sahebkar A. New insights into cellular links between sodium-glucose cotransporter-2 inhibitors and ketogenesis. J Cell Biochem 2022;123:1879-90. [PMID: 36153819 DOI: 10.1002/jcb.30327] [Reference Citation Analysis]
5 Alicic R, Nicholas SB. Diabetic Kidney Disease Back in Focus: Management Field Guide for Health Care Professionals in the 21st Century. Mayo Clinic Proceedings 2022;97:1904-1919. [DOI: 10.1016/j.mayocp.2022.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Seghieri G, Franconi F, Campesi I. Why We Need Sex-Gender Medicine: The Striking Example of Type 2 Diabetes. Diabetology 2022;3:460-469. [DOI: 10.3390/diabetology3030034] [Reference Citation Analysis]
7 Kurata Y, Nangaku M. Dapagliflozin for the treatment of chronic kidney disease. Expert Review of Endocrinology & Metabolism. [DOI: 10.1080/17446651.2022.2099373] [Reference Citation Analysis]
8 Yau K, Dharia A, Alrowiyti I, Cherney DZ. Prescribing SGLT2 Inhibitors in Patients with Chronic Kidney Disease: Expanding Indications and Practical Considerations. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.04.094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 Ujjawal A, Schreiber B, Verma A. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence? Therapeutic Advances in Endocrinology 2022;13:204201882210900. [DOI: 10.1177/20420188221090001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lin CW, Hung SY, Chen IW. Relationship of concomitant anti-diabetic drug administration with sodium-glucose co-transporter 2 inhibitor-related ketosis. J Int Med Res 2022;50:3000605221090095. [PMID: 35352579 DOI: 10.1177/03000605221090095] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Palmer BF, Clegg DJ. Metabolic Flexibility and Its Impact on Health Outcomes. Mayo Clinic Proceedings 2022. [DOI: 10.1016/j.mayocp.2022.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kula AJ. Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD. Pediatr Nephrol 2022. [PMID: 35088160 DOI: 10.1007/s00467-022-05456-x] [Reference Citation Analysis]
13 Solhjou Z, Mcgrath MM. Metabolic Acidosis. nephsap 2022;20:130-144. [DOI: 10.1681/nsap.2022.20.2.5] [Reference Citation Analysis]
14 Triozzi JL, Parker Gregg L, Virani SS, Navaneethan SD. Management of type 2 diabetes in chronic kidney disease. BMJ Open Diabetes Res Care 2021;9:e002300. [PMID: 34312158 DOI: 10.1136/bmjdrc-2021-002300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]